{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:52:14Z","timestamp":1789685534761,"version":"4.0.1"},"reference-count":55,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T00:00:00Z","timestamp":1689033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Risankizumab is a selective, humanized immunoglobulin G1 (IgG1) monoclonal anti-body directed against interleukin (IL)-23 protein. The therapeutic indication of risankizumab is moderate-to-severe plaque psoriasis and psoriatic arthritis. The safety profile of risankizumab is currently defined by data obtained with clinical trials used for the authorization of entry into the market. The aim of this study was to expand information on the safety of risankizumab through a descriptive post-marketing analysis of real-world data regarding serious adverse reactions (SARs) to risankizumab found in the EudraVigilance database. The EudraVigilance database system, containing SARs linked to drugs not yet licensed for the market in the European Union (EU), was used. In EudraVigilance, SARs are described in single individual cases safety reports (ICSRs). More frequently reported serious SARs to risankizumab are associated with, in descending order, infections, cancer, nervous system disorders, cardiac disorders, abnormal laboratory results, pulmonary disorders, conditions aggravated, and skin disorders. Despite the classical limitations of this post-marketing study (lack of denominator, no certainty of causal relationship between the drug and the adverse reaction), analysis of real-world data related to SARs to risankizumab confirms the known safety profile of the drug but, at the same time, stimulates to further go into detail about the occurrence as adverse reactions of malignancies and their sex distribution.<\/jats:p>","DOI":"10.3390\/pharmaceutics15071933","type":"journal-article","created":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T00:50:41Z","timestamp":1689123041000},"page":"1933","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Pharmacovigilance of Risankizumab in the Treatment of Psoriasis and Arthritic Psoriasis: Real-World Data from EudraVigilance Database"],"prefix":"10.3390","volume":"15","author":[{"given":"Fabrizio","family":"Calapai","sequence":"first","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy"},{"name":"Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4075-8065","authenticated-orcid":false,"given":"Ilaria","family":"Ammendolia","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy"},{"name":"Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7286-5674","authenticated-orcid":false,"given":"Luigi","family":"Cardia","sequence":"additional","affiliation":[{"name":"Department of Human Pathology of Adult and Childhood \u201cGaetano Barresi\u201d, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariaconcetta","family":"Curr\u00f2","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8116-4821","authenticated-orcid":false,"given":"Gioacchino","family":"Calapai","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Dental Sciences and Morphological and Functional Imaging, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2663-6387","authenticated-orcid":false,"given":"Emanuela","family":"Esposito","sequence":"additional","affiliation":[{"name":"Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1292-6284","authenticated-orcid":false,"given":"Carmen","family":"Mannucci","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Dental Sciences and Morphological and Functional Imaging, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,7,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/jdv.13854","article-title":"A systematic review of worldwide epidemiology of psoriasis","volume":"31","author":"Michalek","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_2","unstructured":"World Health Organization (2023, March 14). Global Report on Psoriasis: World Health Organization. Available online: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/204417\/9789241565189_eng.pdf.psoriasis?sequence=1."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jaad.2013.11.013","article-title":"Psoriasis prevalence among adults in the United States","volume":"70","author":"Rachakonda","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_4","first-page":"187","article-title":"Prevalence of Psoriasis in Children and Adolescents in the United States: A Claims-Based Analysis","volume":"17","author":"Paller","year":"2018","journal-title":"J. Drugs Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0049-0172(73)90035-8","article-title":"Psoriatic arthritis","volume":"3","author":"Moll","year":"1973","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_7","first-page":"1","article-title":"Risankizumab, an IL-23p19 Inhibitor for Psoriasis: A Review of the Current Literature","volume":"25","author":"McDonald","year":"2020","journal-title":"Ski. Ther. Lett."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1002\/msc.1694","article-title":"The role of IL-23 and the use of IL-23 inhibitors in psoriatic arthritis","volume":"20","author":"Fragoulis","year":"2022","journal-title":"Musculoskelet. Care"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/1346-8138.14941","article-title":"Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the SustaIMM phase 2\/3 trial","volume":"46","author":"Ohtsuki","year":"2019","journal-title":"J. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jdin.2021.09.007","article-title":"Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study","volume":"6","author":"Lytvyn","year":"2021","journal-title":"JAAD Int."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1001\/jamadermatol.2020.0723","article-title":"Efficacy and Safety of Continuous Risankizumab Therapy vs. Treatment Withdrawal in Patients with Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial","volume":"156","author":"Blauvelt","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.2147\/CCID.S364640","article-title":"Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence","volume":"15","author":"Ruggiero","year":"2022","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"15214","DOI":"10.1111\/dth.15214","article-title":"Real world practice indirect comparison between guselkumab and risankizumab: Results from an Italian retrospective study","volume":"35","author":"Ruggiero","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/ced.14979","article-title":"Anti-interleukin-23 for psoriasis in elderly patients: Guselkumab, risankizumab and tildrakizumab in real-world practice","volume":"47","author":"Ruggiero","year":"2022","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1159\/000524199","article-title":"Adverse Effects of Anti-Interleukin-23 Agents Employed in Patients with Psoriasis: A Systematic Review","volume":"238","author":"Naik","year":"2022","journal-title":"Dermatology"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Ruiz-Villaverde, R., Rodriguez-Fernandez-Freire, L., P\u00e9rez-Gil, A., Font-Ugalde, P., and Gal\u00e1n-Guti\u00e9rrez, M. (2022). Risankizumab: Efficacy, Safety, and Survival in the Mid-Term (52 Weeks) in Real Clinical Practice in Andalusia, Spain, According to the Therapeutic Goals of the Spanish Psoriatic Guidelines. Life, 12.","DOI":"10.3390\/life12111883"},{"key":"ref_17","unstructured":"(2023, March 14). EudraVigilance. Available online: https:\/\/www.ema.europa.eu\/en\/human-regulatory\/research-development\/pharmacovigilance\/eudravigilance."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1091978","DOI":"10.3389\/fphar.2023.1091978","article-title":"Pharmacovigilance on cannabidiol as an antiepileptic agent","volume":"14","author":"Ammendolia","year":"2023","journal-title":"Front. Pharmacol."},{"key":"ref_19","unstructured":"(2023, March 10). Risankizumab Authorization Details. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/skyrizi#authorisation-details-section."},{"key":"ref_20","unstructured":"(2023, March 14). EudraVigilance Database. Available online: http:\/\/www.adrreports.eu\/en\/search.html."},{"key":"ref_21","unstructured":"(2023, March 14). Introductory Guide MedDRA Version 25.1. Available online: https:\/\/admin.meddra.org\/sites\/default\/files\/guidance\/file\/intguide_25_1_English.pdf."},{"key":"ref_22","unstructured":"(2016). MedDRA and Pharmacovigilance: A Complex and Little Evaluated Tool. Prescrire Int., 25, 247\u2013250."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1080\/14712598.2022.2132143","article-title":"Anti-IL 23 biologics for the treatment of plaque psoriasis","volume":"22","author":"Vu","year":"2022","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_24","unstructured":"Subramonian, A., Peprah, K., and Picheca, L. (2020). Adalimumab for Adult Patients with Rheumatological Disorders: A Review of Clinical Effectiveness, Canadian Agency for Drugs and Technologies in Health."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Liu, F., and Demosthenes, P. (2022). Real-world data: A brief review of the methods, applications, challenges and opportunities. BMC Med. Res. Methodol., 22.","DOI":"10.1186\/s12874-022-01768-6"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/jdv.18314","article-title":"Risankizumab shows faster response in bio na\u00efve than in bio-experienced psoriatic patients","volume":"36","author":"Mastorino","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2147\/CCID.S296544","article-title":"Risankizumab for the Treatment of Moderate to Severe Psoriasis: Impact on Health-Related Quality of Life and Psychological Wellbeing","volume":"16","author":"Gilaberte","year":"2023","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1056\/NEJMoa1607017","article-title":"Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis","volume":"376","author":"Papp","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s12026-022-09356-y","article-title":"Anti-IL23 biologic therapies in the treatment of psoriasis: Real-world experience versus clinical trials data","volume":"71","author":"Ruggiero","year":"2023","journal-title":"Immunol. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s13555-021-00490-3","article-title":"Long-Term Safety and Efficacy of Risankizumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Results from a Phase 2 Open-Label Extension Trial","volume":"11","author":"Papp","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s00403-021-02200-7","article-title":"Risankizumab in real life: Preliminary results of efficacy and safety in psoriasis during a 16-week period","volume":"314","author":"Megna","year":"2022","journal-title":"Arch. Dermatol. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1093\/bjd\/ljad039","article-title":"Increased reporting of cerebrovascular accidents with use of risankizumab observed in the Food and Drug Administration Adverse Events Reporting System (FAERS)","volume":"188","author":"Egeberg","year":"2023","journal-title":"Br. J. Dermatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1169735","DOI":"10.3389\/fimmu.2023.1169735","article-title":"Adverse events with risankizumab in the real world: Postmarketing pharmacovigilance assessment of the FDA adverse event reporting system","volume":"14","author":"Shu","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_34","unstructured":"(2023, March 14). Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/skyrizi-epar-product-information_en.pdf."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e14487","DOI":"10.1111\/dth.14487","article-title":"Efficacy and safety of Risankizumab in moderate to severe psoriasis: A systematic review and meta-analysis","volume":"34","author":"Singh","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1136\/annrheumdis-2021-221019","article-title":"Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial","volume":"81","author":"Kristensen","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/annrheumdis-2021-221048","article-title":"Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial","volume":"81","author":"Papp","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_38","first-page":"2122","article-title":"Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 2 study","volume":"62","author":"Papp","year":"2022","journal-title":"Rheumatology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1080\/14740338.2020.1736034","article-title":"A drug safety evaluation of risankizumab for psoriasis","volume":"19","author":"Huang","year":"2020","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"a028530","DOI":"10.1101\/cshperspect.a028530","article-title":"Interleukin (IL)-12 and IL-23 and Their Conflicting Roles in Cancer","volume":"10","author":"Yan","year":"2018","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s40257-017-0337-2","article-title":"Malignancy Risk and Recurrence with Psoriasis and its Treatments: A Concise Update","volume":"19","author":"Geller","year":"2018","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"687432","DOI":"10.3389\/fonc.2021.687432","article-title":"Incidence of Skin Cancer in Patients with Chronic Inflammatory Cutaneous Diseases on Targeted Therapies: A Systematic Review and Meta-Analysis of Observational Studies","volume":"11","author":"Crisafulli","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/bjd.20818","article-title":"Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis","volume":"186","author":"Gordon","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Butr\u00f3n-Bris, B., Daud\u00e9n, E., and Rodr\u00edguez-Jim\u00e9nez, P. (2021). Psoriasis Therapy and Skin Cancer: A Review. Life, 11.","DOI":"10.3390\/life11101109"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2042098619882819","DOI":"10.1177\/2042098619882819","article-title":"Evaluation of quantitative signal detection in EudraVigilance for orphan drugs: Possible risk of false negatives","volume":"10","author":"Sardella","year":"2019","journal-title":"Ther. Adv. Drug Saf."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/BOR.0000000000000152","article-title":"Recognizing and managing comorbidities in psoriatic arthritis","volume":"27","author":"Ogdie","year":"2015","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"378","DOI":"10.3899\/jrheum.170379","article-title":"Gaps in Diagnosis and Treatment of Cardiovascular Risk Factors in Patients with Psoriatic Disease: An International Multicenter Study","volume":"45","author":"Eder","year":"2018","journal-title":"J. Rheumatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e000062","DOI":"10.1161\/JAHA.113.000062","article-title":"Psoriasis and major adverse cardiovascular events: A systematic review and meta-analysis of observational studies","volume":"2","author":"Armstrong","year":"2013","journal-title":"J. Am. Heart Assoc."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/acr.22926","article-title":"Risk of Cardiovascular Morbidity in Patients with Psoriatic Arthritis: A Meta-Analysis of Observational Studies","volume":"69","author":"Polachek","year":"2017","journal-title":"Arthritis Care Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1365-4632.2011.05430.x","article-title":"Risk and predictors of cardiovascular disease in psoriasis: A population-based study","volume":"52","author":"Dierkhising","year":"2013","journal-title":"Int. J. Dermatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.3389\/fimmu.2018.01668","article-title":"Psoriasis, Cardiovascular Events, and Biologics: Lights and Shadows","volume":"9","author":"Caiazzo","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","article-title":"The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: A systematic review and meta-analysis","volume":"74","author":"Roubille","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/j.jid.2017.06.001","article-title":"Does Treatment of Psoriasis Reduce Cardiovascular Comorbidities?","volume":"137","author":"Lebwohl","year":"2017","journal-title":"J. Investig. Dermatol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"And\u00fajar, I., Esplugues, J.V., and Garc\u00eda-Mart\u00ednez, P. (2022). Looking beyond the Skin: Pathophysiology of Cardiovascular Comorbidity in Psoriasis and the Protective Role of Biologics. Pharmaceuticals, 15.","DOI":"10.3390\/ph15091101"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Woods, R.H. (Br. J. Clin. Pharmacol., 2022). Potential cerebrovascular accident signal for risankizumab: A disproportionality analysis of the FDA Adverse Event Reporting System (FAERS), Br. J. Clin. Pharmacol., online ahead of print.","DOI":"10.1111\/bcp.15581"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/15\/7\/1933\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:10:49Z","timestamp":1760127049000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/15\/7\/1933"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,11]]},"references-count":55,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["pharmaceutics15071933"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics15071933","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,11]]}}}